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Two unrelated patients with GATA2-haploinsufficiency developed a hemophagocytic
lymphohistiocytosis (HLH)-like disease during a varicella zoster virus (VZV) infection.
High copy numbers of VZV were detected in the blood, and the patients were
successfully treatedwith acyclovir and intravenous immunoglobulins. After treatment with
corticosteroids for the HLH, both patients made a full recovery. Although themechanisms
leading to this disease constellation have yet to be characterized, we hypothesize that
impairment of the immunoregulatory role of NK cells in GATA2-haploinsufficiency may
have accentuated the patients’ susceptibility to HLH. Expansion of a double negative
T-lymphocytic population identified with CyTOF could be a further factor contributing
to HLH in these patients. This is the first report of VZV-triggered HLH-like disease in
a primary immunodeficiency and the third report of HLH in GATA2-haploinsufficiency.
Since HLH was part of the presentation in one of our patients, GATA2-haploinsufficiency
represents a potential differential diagnosis in patients presenting with the clinical features
of HLH—especially in cases of persisting cytopenia after recovery from HLH.
Keywords: varicella-zoster virus, hemophagocytic lymphohistiocytosis, GATA2 deficiency, primary
immumunodeficiencies, NK cell abnormalities, TCRγδ T cells
BACKGROUND
Germline mutations leading to haploinsufficiency of Guanin-adenine-thymine-adenine 2 binding
protein (GATA2) represent the underlying cause of a disorder encompassing primary
immunodeficiency (PID), hematological malignancies and vascular/lymphatic abnormalities
(1). The clinical spectrum of GATA2-haploinsufficiency is very variable and ranges from an
asymptomatic condition to a potentially life-threatening disease. Typical syndromes related
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to GATA2-haploinsufficiency include primary lymphoedema
with myelodysplasia (Emberger syndrome), monocytopenia and
mycobacterial infection (MonoMAC) syndrome, and dendritic
cell, monocyte, B and NK lymphoid (DCML) deficiency (2).
In addition to unusual infections by atypical mycobacteria,
patients may have increased susceptibility to other bacterial
or viral pathogens (e.g., human papilloma virus, varicella
zoster virus (VZV), and Epstein-Barr virus (EBV)). Patients are
also at higher risk of developing hematological malignancies
like myelodysplastic syndrome and acute myeloid leukemia.
Other disease manifestations include thrombosis, lymphoedema,
pulmonary alveolar proteinosis, deafness, and the emergence of
solid tumors. Allogeneic hematopoietic stem cell transplantation
represents a potentially curative therapy for the hematopoietic
and immunologic manifestations in patients with GATA2-
haploinsufficiency (3).
Varicella zoster virus is one of eight members of the
Herpesviridae family that are human pathogens. Primary
VZV infection causes varicella (“chickenpox”) resulting in
latent infection, which can reactivate and cause herpes zoster
(“shingles”). Although (i) the mechanisms involved in antiviral
defenses have not been fully characterized, and (ii) VZV-specific
antibodies can prevent primary infection, it appears that cellular
immune responses are themost importantmeans of limiting viral
replication and altering the course of the disease. The importance
of certain cellular responses is reflected by the fact that patients
with several different PIDs with hereditary impairments in
the adaptive and innate immune system, including SCID and
CID with missense mutation in IL2RG (4, 5), loss-of-function
mutations in DOCK2 (6) andDOCK8 (7), defects in intrinsic and
innate immunity with loss-of function mutations in TYK2 (8),
IFNGR1 (9), RTEL1 (10, 11), monogenic or digenic deficiencies
in POLR3A and POLR3C (12), and haploinsufficiency in GATA2
(13, 14) are at risk of developing severe VZV-infection, while
those with functional defects in granulocytes and those with pure
agammaglobulinaemia are not.
Hemophagocytic lymphohistiocytosis (HLH) is a
hyperinflammatory syndrome diagnosed following a molecular
diagnosis of primary HLH or when five out of eight
clinical and laboratory criteria are met (15). In addition to
familial hemophagocytic lymphohistiocytosis and X-linked
lymphoproliferative syndrome (XLP), HLH has been described
in association with a variety of PIDs, and the clinical presentation
of some of these cases has recently been summarized (16, 17).
Here, we describe two unrelated patients with GATA2-
haploinsufficiency who developed severe primary VZV infection
together with an HLH-like disease. In addition, we describe
the immunological phenotype of these two patients compared
with healthy controls and with two other patients with GATA2-
haploinsufficiency without VZV infection.
CASE PRESENTATIONS
Patient 1 is an 8-year-old girl who first presented with abdominal
pain, an erythematous, vesicular skin rash (Figure 1A) and
subfebrile body temperatures over a 4-day period. In the
preceding month, the patient had been referred for a medical
workup for persistent warts on the hands and feet. At that
time, recurrent furuncles been noted. On admission, the serum
AST level was 490 U/l (normal range <48), the ALT was 374
U/l (normal range <39), and the LDH was 1619 U/L (normal
range <236). The patient’s blood count and prothrombin time
(PT), activated Partial Thromboplastin Time (aPTT), bilirubin,
fibrinogen, and creatinine levels were all normal. Although the
skin rash was not classic for VZV and could thus not be
unambiguously assigned to VZV infection, empiric treatment
with acyclovir was initiated immediately. A biopsy showed non-
specific changes with spongiosis of the epidermis, perivascular
lymphocytic infiltrates and rare eosinophilic granulocytes. The
patient’s mother reported that the patient had chicken pox
some years before admission. However, we could not detect
anti-VZV antibodies in a serum sample taken 1 month before
admission. Varicella zoster virus DNA was detected in the
patient’s blood (peaking at 537,000 copies/ml) and in the fluid
from skin vesicles. HSV-1 and−2 PCR of vesicle fluid as well
as HHV6, EBV, and CMV PCR of blood were negative. Mild
hypogammaglobulinemia was noted (IgG 6.5 g/l; normal range:
7.6 – 14.5) and intravenous immunoglobulins (0.4 g/kg) were
administered on day 2 and 4 as a supportive treatment. Seven
days after the onset of illness, the skin rash progressed to
targetoid lesions (Figure 1B) and the patient developed fever
and tachy-dyspnoea. Respiratory insufficiency on day 8 after
the onset of illness required mechanical ventilation. A miliary
pattern of pulmonary opacities was noted on a chest X-
ray (Figure 1C). The patient’s laboratory parameters gradually
deteriorated with progression to bicytopenia. On day 13, specific
laboratory findings were noted: anemia (hemoglobin: 73 g/l),
neutropenia (absolute neutrophil count: 710 cells/µL), elevated
ferritin (peak value: 7090 µg/L; normal range 7 – 69), elevated
triglycerides (peak value: 5.8 mmol/L; normal range 0.5 –
2.2), elevated soluble IL-2 receptor (peak value: 1622 pg/ml;
normal range < 477), documentation of haemophagocytosis
in a bone marrow aspirate; an elevated platelet count, and
elevated fibrinogen. The spleen was not enlarged. Overall, the
patient’s clinical and laboratory profile met the diagnostic criteria
for HLH (Table 1), and so treatment with corticosteroids (1.5
mg/kg/d) was initiated on day 13. The patient progressively
recovered from hepatitis, pneumonitis and HLH. Leukocyte
subpopulations, which had contracted during the VZV illness
expanded again thereafter (Supplementary Table 1). The rash
resolved after having progressed from vesicles to scabbing.
Acyclovir was discontinued after 21 days, and corticosteroids
were tapered over a total treatment period of 4 weeks.
A history of persistently low cell counts of neutrophilic
granulocytes and B cells, hypogammaglobulinaemia, and
increased susceptibility to infections (furunculosis and
persistent warts) had prompted us to sequence the patient’s
GATA2 gene. This confirmed the presence of a heterozygous
mutation (c.1172_1175del, p.E391Gfs∗85) compatible with
GATA2-haploinsufficiency.
More than 1 year later, the patient again developed
bicytopenia, hyperferritinaemia, hypertriglyceridaemia,
hypofibrinogenaemia, an elevated soluble IL-2 receptor level,
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FIGURE 1 | Clinical presentation of VZV disease in GATA2-haploinsufficient patient (A) An erytematous, vesicular skin rash on the back of patient 1 with
GATA2-haploinsufficiency, 4 days after the onset of VZV disease. (B) Targetoid lesions on the left arm of the same patient, 7 days after the onset of illness. (C) A chest
X-ray 8 days after the onset of illness, showing diffuse alveolar involvement with a miliary pattern of pulmonary opacities. (D) Histograms showing perforin expression
in CD56+CD16+ lymphocytes from patient 1 (gray), patient 2 (black), an individual with heterozygous A91V PRF1 mutation (green), a healthy control (blue) and
isotype control (red dotted line) as assessed by intracellular flow cytometry.
and transaminitis after an episode of fever of unknown origin.
Treatment with corticosteroids (2 mg/kg/day) and a broad-
spectrum antibiotic was initiated, and the patient recovered. No
pathogen could be identified.
Patient 2 is a 7-year-old boy with known GATA2-
haploinsufficiency who presented with fever, skin rash, and
cough. Three years earlier, the patient had been treated for
recurrent fever, oral aphthosis, and recurrent furunculosis.
Together with the observed lymphopenia (affecting CD4T cells,
B cells, and NK cells) and the presence of treatment-resistant
warts on the patient’s mother’s hands, these immunological
findings prompted us to sequence GATA2 in the patient and
his mother. The diagnosis of GATA2-haploinsufficiency was
confirmed by the presence of a c.(16bp tandem repeat in
exon 4), p.T347fs) mutation. On admission, the boy was
in good general condition. He showed mild fever (38.5◦C),
hepatosplenomegaly and an erythematous, vesicular skin rash
suggestive of chickenpox, prompting empiric intravenous
Frontiers in Immunology | www.frontiersin.org 3 December 2018 | Volume 9 | Article 2766
Prader et al. VZV-Triggred HLH in GATA2-Deficiency
TABLE 1 | HLH features of patient 1 and 2.
HLH criteria: Patient 1 Patient 2
1. Fever ≥38.5 Yes Yes
2. Splenomegaly (palpable below costal margin or
increased size by imagery)
No Yes
3. Cytopenias (affecting ≥2 out of the 3 lineages):
– Hemoglobin (<90 g/l)
– Neutrophilic granulocytes (<1.0 × 109/l)
– Platelet count (<100 × 109/l)
Yes:
73 g/l
0.71 × 109/l
(Plts: not fulfilled)
Yes:
(Hb: not fulfilled)
0.38 × 109/l
53 × 109/l
4. Hemophagocytosis (in bone marrow or CSF) Yes NA
5. Hyperferritinemia (≥500 µg/l) Yes: 7,090 µg/l Yes: 4,510 µg/l
6. Hypertriglyceridemia (fasting level: ≥3.0 mmol/l) or
hypofibrinogenemia (≤1.5 g/l)
Yes: triglyceride fasting level: 5.8 mmol/l NA
7. Increased soluble CD25 (≥2,400 U/l) No (although above normal level) No
8. Decreased protein expression (Perforin, SAP, or
XIAP) or deficient NK-cell degranulation
Perforin expression in lower range of normal,
NK cell degranulation on the threshold
Perforin expression in lower range of normal,
NK cell degranulation on the threshold
Totally fulfilled criteria* (≥ 5 out of 8) Criteria fulfilled (5 out of 8 fulfilled) Criteria not fulfilled, not all analyzed (4 out
of 6 fulfilled)
* Diagnosis of an active HLH episode can be established if 5 out of the 8 criteria listed above are fulfilled. NA, not analyzed.
treatment with acyclovir. Mild hypogammaglobulinemia was
known in this patient (IgG 6.1 g/l; normal range: 6.7 –
12.1) but was not substituted before. After admission, varicella
immunoglobulins (22 IU/kg) and intravenous immunoglobulins
(0.4 g/kg) were administred on day 0 and 2, respectively.
Diagnosis was confirmed by positive VZV PCR in samples
from skin lesions and peripheral blood (peak value: 183,572
copies/ml). CMV PCR of blood was negative. Low EBV
DNA load had been detected in this patient 1 month
before VZV-infection and EBV DNA load slightly increased
during VZV-infection (max 424 copies/ml, normal range
<100) and became negative 2 months thereafter. On day
2, the patient developed pancytopenia (hemoglobin: 95 g/L;
absolute neutrophil count: 380 cells/µL; platelet count: 53
G/L). On days 2 and 3, specific laboratory findings were
noted: an elevation in serum ferritin (from 820 to 4,510
µg/L within 3 days) and triglycerides (from 0.6 to 2.2
mmol/l within 3 days). The clinical signs and laboratory
results were consistent with a diagnosis of developing HLH
(Table 1), and so treatment with corticosteroids (2 mg/kg/d) was
initiated.
Natural killer cell function assays revealed a slight
reduction in degranulation (as assessed by CD107a
expression) in both patients (9.4% in patient 1 and 8.8%
in patient 2; normal range >10%) upon stimulation with
K562 target cells. Perforin expression in both GATA2-
haploinsufficient patients was within the lower range
compared to an adult control and within the range of a
control individual with known heterozygous A91V-perforin-
mutation. SAP and XIAP expression in patient 2 were normal
(Figure 1D).
Five months before the VZV episode, patient 2 was included,
together with two other patients with GATA2-haploinsufficiency
(patients 3 and 4), in a pilot study aimed at characterizing the
immunological phenotype of this disease using mass cytometry
(CyTOF). Patient 3 is the mother of patient 2 with an identical
genotype (p.T347fs). In patient 4, amutation inGATA2 c.593delC
was found, which is predicted to result in p.Ala198fs with a
premature stop codon 19 positions downstream. To visualize
the lymphocyte pattern differences in peripheral blood samples
from these three patients and three healthy controls, we used t-
Disturbed Stochastic Neighbor Embedding (tSNE) to visualize
mass cytometry datasets (Figures 2A,B), using the antibody
panel shown in Supplementary Table 2. All patients with
GATA2-haploinsufficiency had markedly reduced peripheral
blood B cells, NK cells and monocytes (Figure 2C). The patients
furthermore displayed an exceedingly high frequency of a CD3+
CD56+ CD16- CD8- CD4- cell population (“XYZ-population”
in Figures 2A,D,E). Although largely different in ratios, this
and the monocyte population retained the same phenotype
as the ones present in healthy controls (Figure 2D). A large
proportion of the CD3+ CD56+ CD16- CD8- CD4- cell
population phenotypically corresponded to TCRγδ+ or NKT
lymphocytes. This was confirmed by flow cytometry analysis of
samples collected at different time points using a TCRγδ specific
antibody (Figure 2F). A marked accumulation (20% to 30% of
lymphocytes) of these TCRγδ+ cells was noted between the age
of 4 and 8 years in patient 2. Patient 4 also showed an elevated
percentage of these cells (10% to 20% of lymphocytes between
the age of 12 and 16 years). On the contrary, TCRγδ+ cells in
patient 1 and patient 3 remained below 5% of lymphocytes during
the period of monitoring (between the age of 8 and 10 years for
patient 1, and 22 and 25 years for patient 3), raising the possibility
that populations other than TCRγδ+ T cells are expanded in
GATA2-haploinsufficiency (Figure 2F).
DISCUSSION
Here we describe two patients with GATA2-haploinsufficiency
with severe VZV infection and HLH-like disease. Although
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FIGURE 2 | High-dimensional mass cytometry for the analysis of immune populations in GATA2-haploinsufficient patients PBMCs of 3 patients (patients 2–4) and 3
healthy controls were stained with 27 heavy-metal labeled antibodies (Supplementary Table 2) and acquired on a CYTOF2 mass cytometer. (A) Cells identified
(Continued)
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FIGURE 2 | as CD45+ were exported, downsampled to 900 events and the combined dataset (5,400 cells) subjected to dimensionality reduction using the t-SNE
algorithm. Density plot of total (left panel), control (middle panel) and patient (right panel) cells based on tSNE analysis. The manually gated XYZ population consist of
closely grouped cells present mainly in the patients and not belonging to any immune subpopulation defined by manual annotation. (B) Color-coded manual gates are
plotted by density for the combined dataset. (C) Density plots of the different subpopulations in patients and controls with the fraction out of all CD45+ cells indicated.
(D) Histograms of markers with the largest expression discrepancies between patients and controls in the XYZ population and among monocytes based on visual
analysis. (E) Percentages of XYZ cells from the CyTOF data, out of all CD45+ plotted for patient 2 (HLH), the 2 additional patients with germline GATA2-mutations
(patient 3 and 4) and the 3 healthy controls. (F) Timecourse of TCRγδ+ cells (percentage of lymphocytes) measured by conventional flow cytometry in
GATA2-haploinsufficient patients 1 to 4.
increased susceptibility to VZV is regularly seen in patients
with GATA2-haploinsufficiency, the combination of GATA2-
haploinsufficiency and HLH-like disease has not been described
so far.
Features consistent with HLH included fever, cytopenia
involving at least two cell lineages, and elevated serum ferritin
(>4,500 µg/L). Haemophagocytosis in the bone marrow aspirate
and elevated serum levels of triglycerides and of soluble IL-2R
in one of the patients are additional characteristics suggestive
of HLH. Of note, patients with GATA2-haploinsufficiency may
have baseline cytopenias, as this was the case in patient 2.
Diagnosis of HLH in patients with baseline cytopenias must be
made carefully with special attention on the dynamics of clinical
course and laboratory parameters to ensure early recognition.
Both patients were successfully treated for VZV and HLH, and
recovered without sequelae. Although the occurrence of HLH
has been reported in a variety of PIDs (5, 6), the combination
of GATA2-haploinsufficiency and HLH has, to the best of our
knowledge, only been described twice in the context of herpes
virus infection: once in a patient with herpes simplex virus
infection (18), and once in a patient with marked EBV viremia
and an EBV-driven T cell lymphoproliferative disease (19), but
not with VZV. In one of our patients, the HLH-like syndrome
was already present when the PID was diagnosed. GATA2-
haploinsufficiency is therefore a potential differential diagnosis
in patients presenting with the clinical features of HLH –
especially in cases of persisting cytopenia after recovery from
HLH.
In the two patients with GATA2-haploinsufficiency described
here, VZV infection had probably triggered the HLH-like
syndrome. Interestingly, the medical history of patient 1 was
suggestive of prior VZV primary infection but no VZV-specific
antibodies were detected in serum taken before the HLH-
eliciting VZV infection. Patients with GATA2-haploinsufficiency
are known to be at risk for unusual or more severe herpes
virus infections (2, 20), but the precise mechanism has yet to
be defined. Severe VZV-infection was part of the presentation
of one of the earliest reported patients reported by Biron et
al. (13), subsequently characterized as GATA2-haploinsufficient
patient (14). Although VZV can trigger HLH in patients under
immunosuppression or in otherwise healthy individuals, the
literature, however, contains, to the best of our knowledge, no
reports on VZV-triggered HLH in PIDs (16, 17, 21). Perturbation
of the immune homeostasis between viral control and immune
activation is thought to be an important factor in the viral
triggering of HLH. This hypothesis is supported by data from
murine models of HLH, where CD8T cells with genetic defects
in cytotoxic activity and interferon gamma have a pivotal role
in the pathogenesis of an HLH-like condition (22, 23). Although
NK cell depletion does not prevent the development of HLH (22),
NK cells were shown to control T cells via a perforin-dependent
mechanism (24–26). Altered cytotoxic granule content associated
with adaptive NK cell differentiation has been previously shown
in GATA2-haploinsufficient patient (27). In accordance with
these findings, patient 1 and 2 showed low perforin expression.
Thus, NK cell deficiency might not only predispose to a
susceptibility to infections but might have accentuated the
susceptibility to HLH in our GATA2-haploinsufficient patients
due to a deficiency in an important immunoregulatory role of
NK cells.
Our analysis of the immunological repertoire in GATA2-
haploinsufficient patients shows that there is an unexpected
expansion of CD3+ CD56+ CD16- CD8- CD4- cells. Using
flow cytometry, we confirm a high proportion of TCRγδ+ cells
in peripheral blood of patient 2. The normal proportion of
TCRγδ+ cells in patient 1 confirms that HLH can occur without
TCRγδ+ cell expansion. Also, low percentage of TCRγδ+ T
lymphocytes in patient 3, together with the evidence of expanded
CD3+ CD56+ CD16- CD8- CD4- cells, raises the possibility
that other cell types, like NKT cells, can expand in GATA-
2 deficiencies. The cause behind the expansion in TCRγδ+
cells in two of the four GATA2-haploinsufficient patients is
unknown.
GATA2-haploinsufficiency is associated with poor maturation
and low numbers of peripheral blood NK cells (also noted in
our patients before VZV infection). Slightly reduced NK cell
degranulation was observed in both GATA2-haploinsufficient
patients with HLH. This is consistent with a previous report
of decreased NK cell cytotoxicity in a GATA2-haploinsufficient
patient (18). It is tempting to speculate that deficiency in NK cell
number and function disturbs the immunoregulatory role of NK
cells and makes GATA2-haploinsufficient patients more prone to
HLH-like disease. HLH-like disease might, therefore, reflect not
only impaired infection control but also a genetic predisposition
to hyperinflammation.
Since GATA-2 haploinsufficiency is characterized by
monocytopenia, together with B, NK and DC lymphopenia,
discovering a population expanded in GATA-2 patients
is remarkable. Because the phenotype of this T cells
resembles that of TCRγδ+ T lymphocytes and NKT cells,
we are suggesting that this could be the hyper-responsive
population driving HLH symptoms. The relevance of this
population, or any other, in causing HLH is unclear but
the innate-like phenotype of TCRγδ+ T lymphocytes
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and NKT cells, with their capacity of secreting large
amounts of inflammatory cytokines, is suggestive that these
populations could escalate a viral infection to an HLH like
episode.
The present report thus expands the clinical spectrum
of GATA2-haploinsufficiency and highlights new aspects
of immune dysregulation in this disorder. However, the
mechanisms leading to HLH-like disease have yet to be fully
understood.
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